Your browser doesn't support javascript.
loading
A clinical trial on Conbercept for macular edema secondary to central retinal vein occlusion / 国际眼科杂志(Guoji Yanke Zazhi)
International Eye Science ; (12): 1901-1904, 2017.
Article in Chinese | WPRIM | ID: wpr-641082
ABSTRACT

AIM:

To investigate the effect and safety of intravitreous injection of conbercept ( 0. 5mg ) on macular edema secondary to central retinal vein occlusion ( CRVO) . ·

METHODS:

According to the selective criteria, from October 2014 to October 2015, 48 cases ( 48 eyes ) of patients with macular edema secondary to CRVO were collected, which were divided randomly into conbercept group ( 24 cases, 24 eyes ) and control group ( triamcinolone acetonide 4mg/0. 1mL, 24 cases , 24 eyes ) . The best-corrected visual acuity ( BCVA ) , intraocular pressure, intravitreous injection, fundus oculi, central macular thickness ( CMT ) and related complications were observed before and 1wk, 1, 3, 6 and 12mo after intravitreous injection. ·

RESULTS:

There was no difference on BCVA, intraocular pressure, intravitreous injection, fundus oculi and CMT between the two groups before operations ( P>0.05). There were no significant differences (P>0.05) of the BCVA between two groups after treatment for 1wk, 1, 3, 6 and 12mo. Before and after treatment, the decrease of CMT in conbercept group was respectively 130. 17 ± 1. 72μm, 253. 33 ±3. 14μm, 318. 00±1. 41μm, 20. 01±1. 21μm and 15. 09 ± 1. 41μm, and no related complications. The decrease of CMT in control group was respectively 132. 5± 2.07μm, 249.67±1.21μm, 317.50±4.23μm, 18.01±1.41μm and 16. 09 ± 1. 31μm, and no related complications. There were no significant differences (F=6. 882, P=0. 663>0. 05) of CMT between two groups after treatment for 1wk, 1, 3, 6 and 12mo. Injection times were respectively 2. 83 ± 0. 72 and 3. 17 ± 0. 71 in control group and conbercept group, and the difference between two groups has no statistical significance (P>0. 05). There were 4 cases (17%) of paracentesis of anterior chamber, 3 cases ( 13%) of intraocular hypertension and 1 case ( 4%) of complicated cataract in control group. There was no related complications in conbercept group. ·

CONCLUSION:

Intravitreous injection of conbercept for macular edema secondary to CRVO is effective, safe and less complications.

Full text: Available Index: WPRIM (Western Pacific) Type of study: Controlled clinical trial Language: Chinese Journal: International Eye Science Year: 2017 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Type of study: Controlled clinical trial Language: Chinese Journal: International Eye Science Year: 2017 Type: Article